What can we expect from BMY's 2025 Q1 EPS?

**Bristol Myers Squibb's (BMY) 2025 Q1 EPS is expected to show significant year-over-year growth.** Here's a detailed analysis:

1. **Analyst Expectations**: Analysts anticipate that BMY will post earnings per share (EPS) of $1.55 for the quarter ending Q1 2025. This EPS figure represents a substantial year-over-year growth of 135.23% compared to the corresponding quarter of the previous year.

|code|Ticker|Name|Date|Diluted EPS YoY|Diluted EPS|market_code|
|---|---|---|---|---|---|---|
|BMY|BMY.N|Bristol-Myers Squibb|2024 Q2|-16.161616161616166|0.83|169|
|BMY|BMY.N|Bristol-Myers Squibb|2024 Q3|-35.48387096774194|0.6|169|
|BMY|BMY.N|Bristol-Myers Squibb|2024 Q4|-95.40229885057471|0.04|169|

2. **Market Performance and Guidance**: BMY's stock has outpaced the S&P 500's daily loss in recent trading sessions, showing relative strength in the market. The company's earnings report for Q1 2025 is scheduled for April 24, 2025. The company's FY 2025 earnings guidance provides an EPS guidance of $6.550-6.850, compared to the consensus EPS estimate of $6.920. This suggests that the expected EPS of $1.55 for Q1 2025 falls within the range of the company's guidance and analyst expectations.
3. **Revenue Expectations**: Along with the EPS, the company's revenue for Q1 2025 is expected to be $10.69 billion, indicating a 9.94% decline year-over-year. This decline in revenue is primarily due to the impact of cheaper generics on demand for some older medicines, as mentioned in the company's outlook for 2025.
4. **Full-Year Outlook**: For the entire fiscal year 2025, the Zacks Consensus Estimates predict earnings of $6.75 per share and revenue of $45.59 billion. These figures indicate significant year-over-year changes of +486.96% in earnings and -5.6% in revenue, respectively. The expected EPS of $1.55 for Q1 2025 is a part of the company's full-year earnings trajectory, which suggests a strong earnings performance despite the anticipated revenue decline.

In conclusion, BMY's 2025 Q1 EPS is expected to show robust growth, primarily driven by the company's diversified portfolio and the success of new products like Cobenfy, despite the challenges posed by cheaper generics and revenue decline in certain legacy products.